23 results on '"Dioun S"'
Search Results
2. OP013/#417 Cost-effectiveness of dostarlimab in advanced recurrent deficient mismatch repair endometrial cancer patients
- Author
-
Dioun, S, primary, Chen, L, additional, Gockley, A, additional, Melamed, A, additional, St Clair, C, additional, Tergas, A, additional, Hou, J, additional, Collado, F, additional, and Wright, J, additional
- Published
- 2021
- Full Text
- View/download PDF
3. Minimally invasive surgery for suspected early‐stage ovarian cancer; a cost‐effectiveness study.
- Author
-
Dioun, S, Chen, L, Melamed, A, Gockley, A, St. Clair, CM, Hou, JY, Tergas, AI, Khoury‐Collado, F, Elkin, E, Accordino, M, Hershman, DL, and Wright, JD
- Subjects
- *
MINIMALLY invasive procedures , *OVARIAN cancer , *COST effectiveness , *ABDOMEN , *OVARIAN cysts - Abstract
Objective: While there are a number of benefits to minimally invasive surgery (MIS) for women with ovarian cysts, there is an increased risk of ovarian capsule rupture during the procedure, which could potentially seed the abdominal cavity with malignant cells. We developed a decision model to compare the risks, benefits, effectiveness and cost of MIS versus laparotomy in women with ovarian masses. Design: Cost‐effectiveness study Population: Hypothetical cohort of 10 000 women with ovarian masses who were undergoing surgical management. Methods: The initial decision point in the model was performance of surgery via laparotomy or a MIS approach. Model probabilities, costs and utility values were derived from published literature and administrative data sources. Extensive sensitivity analyses were conducted to assess the robustness of the findings. Main outcome measures: The primary outcome was the cost‐effectiveness of MIS versus laparotomy for women with a pelvic mass measured by incremental cost‐effectiveness ratios (ICERs). Results: MIS was the least costly strategy at $7,732 per women on average, compared with $17,899 for laparotomy. In our hypothetical cohort of 10 000 women, there were 64 cases of ovarian rupture in the MIS group and 53 in the laparotomy group, while there were 26 cancer‐related deaths in the MIS group and 25 in the laparotomy group. MIS was more effective than laparotomy (188 462 QALYs for MIS versus 187 631 quality adjusted life years [QALYs] for laparotomy). Thus, MIS was a dominant strategy, being both less costly and more effective than laparotomy. These results were robust in a variety of sensitivity analyses. Conclusion: MIS constitutes a cost‐effective management strategy for women with suspicious ovarian masses. MIS is a cost‐effective management strategy for women with suspicious ovarian masses. MIS is a cost‐effective management strategy for women with suspicious ovarian masses. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Obesity significantly reduces the sentinel lymph node detection rate in women with endometrial cancer
- Author
-
Soliman, P.T., primary, Nick, A.M., additional, Sun, C.C.L., additional, Dioun, S., additional, Pal, N., additional, Abdelwahab, M., additional, Frumovitz, M., additional, Ramirez, P.T., additional, Lu, K.H., additional, and Westin, S.N., additional
- Published
- 2016
- Full Text
- View/download PDF
5. Robotic simulation: Setting benchmarks for the new user and implementation of a trainee curriculum
- Author
-
Dioun, S., primary, Fleming, N.D., additional, Munsell, M.F., additional, Lee, J., additional, Frumovitz, M., additional, Ramirez, P.T., additional, and Soliman, P.T., additional
- Published
- 2016
- Full Text
- View/download PDF
6. Sentinel lymph node mapping accurately identifies positive nodes in women with high risk endometrial cancer
- Author
-
Soliman, P.T., primary, Westin, S.N., additional, Sun, C.C.L., additional, Dioun, S., additional, Frumovitz, M., additional, Nick, A.M., additional, Fleming, N.D., additional, Ramirez, P.T., additional, Levenback, C.F., additional, and Lu, K.H., additional
- Published
- 2015
- Full Text
- View/download PDF
7. Considering screening for hereditary cancer syndromes at the time of obstetrical prenatal carrier screening.
- Author
-
Perez L, Dioun S, Primiano M, Blank SV, Lipkin S, Ahsan MD, Brewer J, Fowlkes RK, Abdul-Rahman O, Hou J, Wright JD, Kang HJ, Sharaf R, Prabhu M, and Frey MK
- Published
- 2024
- Full Text
- View/download PDF
8. Fertility-preserving treatment for stage IA endometrial cancer: a systematic review and meta-analysis.
- Author
-
Suzuki Y, Ferris JS, Chen L, Dioun S, Usseglio J, Matsuo K, Xu X, Hershman DL, and Wright JD
- Abstract
Objective: The increasing use of fertility-preserving treatments in reproductive-aged patients with early-stage endometrial cancer necessitates robust evidence on the effectiveness of oral progestins and levonorgestrel-releasing intrauterine device. We conducted a systematic review and meta-analysis to examine the outcomes following these 2 primary progestin-based therapies in reproductive-aged patients with early-stage endometrial cancer., Data Sources: We conducted a systematic review of observational studies and randomized controlled trials following the Cochrane Handbook guidance. We conducted a literature search of 5 databases and 1 trial registry from inception of the study to April 16, 2024., Study Eligibility Criteria: Studies reporting complete response within 1 year in reproductive-aged patients with clinical stage IA endometrioid cancer undergoing progestin therapy treatment were included. We used data from both observational and randomized controlled studies., Study Appraisal and Synthesis Methods: The primary exposure assessed was the type of progestational treatment (oral progestins or LNG-IUD). The primary outcome was the pooled proportion of the best complete response (CR) within 1 year of primary progestational treatment. We performed a proportional meta-analysis to estimate the treatment response. Sensitivity analyses were performed by removing studies with extreme effect sizes or removing grade 2 tumors. The risk of bias was assessed in each study using the Joanna Briggs Institute critical appraisal checklist., Results: Our analysis involved 754 reproductive-aged patients diagnosed with endometrial cancer, with 490 receiving oral progestin and 264 receiving levonorgestrel-releasing intrauterine device as their primary progestational treatment. The pooled proportion of the best complete response within 12 months of oral progestin and levonorgestrel-releasing intrauterine device treatment were 66% (95% CI, 55-76) and 86% (95% CI, 69-95), respectively. After removing outlier studies, the pooled proportion was 66% (95% CI, 57-73) for the oral progestin group and 89% (95% CI, 75-96) for the levonorgestrel-releasing intrauterine device group, showing reduced heterogeneity. Specifically, among studies including grade 1 tumors, the pooled proportions were 66% (95% CI, 54-77) for the oral progestin group and 83% (95% CI, 50-96) for the levonorgestrel-releasing intrauterine device group. The pooled pregnancy rate was 58% (95% CI, 37-76) after oral progestin treatment and 44% (95% CI, 6-90) after levonorgestrel-releasing intrauterine device treatment., Conclusion: This meta-analysis provides valuable insights into the effectiveness of oral progestins and levonorgestrel-releasing intrauterine device treatment within a 12-month timeframe for patients with early-stage endometrial cancer who desire to preserve fertility. These findings have the potential to assist in personalized treatment decision-making for patients., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
9. Levonorgestrel-releasing intrauterine device therapy vs oral progestin treatment for reproductive-aged patients with endometrial intraepithelial neoplasia: a systematic review and meta-analysis.
- Author
-
Suzuki Y, Ferris JS, Chen L, Dioun S, Usseglio J, Matsuo K, Xu X, Hershman DL, and Wright JD
- Subjects
- Adult, Female, Humans, Pregnancy, Administration, Oral, Carcinoma in Situ drug therapy, Carcinoma in Situ pathology, Treatment Outcome, Endometrial Neoplasms drug therapy, Endometrial Neoplasms pathology, Intrauterine Devices, Medicated, Levonorgestrel administration & dosage, Pregnancy Rate, Progestins administration & dosage
- Abstract
Background: We conducted a systematic review and meta-analysis to examine outcomes of patients with endometrial intraepithelial neoplasia treated with oral progestins or a levonorgestrel-releasing intrauterine device (IUD)., Methods: We conducted a systematic review across 5 databases to examine outcomes of progestational treatment (oral progestins or levonorgestrel-releasing IUD) for patients with endometrial intraepithelial neoplasia. The primary outcome was the best complete response rate within 12 months of primary progestational treatment. Sensitivity analyses were performed by removing studies with extreme effect sizes. Secondary outcomes included the pooled pregnancy rate., Results: We identified 21 eligible studies, including 824 premenopausal patients with endometrial intraepithelial neoplasia, for our meta-analysis. Among these, 459 patients received oral progestin, and 365 patients received levonorgestrel-releasing IUD as a primary progestational treatment. The pooled best complete response proportion within 12 months was 82% (95% confidence interval [CI] = 69% to 91%) following oral progestin treatment and 95% (95% CI = 81% to 99%) following levonorgestrel-releasing IUD treatment. After removing outlier studies, the pooled proportion was 86% (95% CI = 75% to 92%) for the oral progestin group and 96% (95% CI = 91% to 99%) for the levonorgestrel-releasing IUD group, with reduced heterogeneity. The pooled pregnancy rate was 50% (95% CI = 35% to 65%) after oral progestin and 35% (95% CI = 23% to 49%) after levonorgestrel-releasing IUD treatment., Conclusions: This meta-analysis provides data on the effectiveness of oral progestins and levonorgestrel-releasing IUD treatment within 12 months of treatment among premenopausal patients with endometrial intraepithelial neoplasia. Although based on small numbers, the rate of pregnancy after treatment is modest. These data may be beneficial for selecting progestational therapies that allow fertility preservation for patients with endometrial intraepithelial neoplasia., (© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
10. Survival rates in Hispanic/Latinx subpopulations with cervical cancer associated with disparities in guideline-concordant care.
- Author
-
Dinicu AI, Dioun S, Wang Y, Huang Y, Wright JD, and Tergas AI
- Subjects
- Humans, Female, Middle Aged, Survival Rate, Adult, Aged, United States epidemiology, Guideline Adherence statistics & numerical data, Neoplasm Staging, Practice Guidelines as Topic, Uterine Cervical Neoplasms therapy, Uterine Cervical Neoplasms ethnology, Uterine Cervical Neoplasms mortality, Uterine Cervical Neoplasms pathology, Hispanic or Latino statistics & numerical data, Healthcare Disparities statistics & numerical data, Healthcare Disparities ethnology
- Abstract
Background: Failure to deliver guideline-concordant treatment may contribute to disparities among Hispanic/Latinx cervical cancer patients. This study investigated the association between survival rates in Hispanic/Latinx subpopulations and the provision of guideline-concordant care., Methods: We analyzed patients with primary cervical cancer from 2004 to 2019 (National Cancer Database). We developed nine quality metrics based on FIGO staging (2009). Clinical and demographic covariates were analyzed using Chi-squared tests. Adjusted associations between receipt of guideline-concordant care and races and ethnicities were analyzed using multivariable marginal Poisson regression models. Adjusted Cox proportional hazard models were utilized to evaluate survival probability., Results: A total of 95,589 patients were included. Hispanic/Latinx and Non-Hispanic Black (NHB) populations were less likely to receive guideline-concordant care in four and five out of nine quality metrics, respectively. Nonetheless, the Hispanic/Latinx group exhibited better survival outcomes in seven of nine quality metrics. Compared to Mexican patients, Cuban patients were 1.17 times as likely to receive timely initiation of treatment in early-stage disease (RR 1.17, 95% CI 1.04-1.37, p < 0.001). Puerto Rican and Dominican patients were, respectively, 1.16 (RR 1.16, 95% CI 1.07-1.27, p < 0.001) and 1.19 (RR 1.19, 95% 1.04-1.37, p > 0.01) times as likely to undergo timely initiation of treatment in early-stage disease. Patients of South or Central American (RR 1.18, 95% CI 1.10-1.27, p < 0.001) origin were more likely to undergo timely initiation of treatment in locally advanced disease., Conclusion: Significant differences in survival were identified among our cohort despite the receipt of guideline concordant care, with notably higher survival among Hispanic/Latinx populations., Competing Interests: Declaration of competing interest Dr. Tergas participates in an advisory board meeting for Merck. Dr. Wright receives royalties from UpToDate, research funding from Merck, is a journal editor for the American College of Obstetricians and Gynecologists and receives payment for medicolegal consulting pertaining to gynecologic cancer., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
11. Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy.
- Author
-
Dioun S, Chen L, De Meritens AB, St Clair CM, Hou JY, Khoury-Collado F, Pua T, Hershman DL, and Wright JD
- Subjects
- Female, Humans, Cost-Benefit Analysis, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local genetics, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Quality-Adjusted Life Years, DNA Mismatch Repair, Endometrial Neoplasms drug therapy, Endometrial Neoplasms genetics, Phenylurea Compounds, Quinolines, Antibodies, Monoclonal, Humanized
- Abstract
Objective: The recent Study 309-KEYNOTE-775 showed improved survival for lenvatinib plus pembrolizumab compared to chemotherapy in patients with recurrent endometrial cancer. We created a decision model to compare the cost-effectiveness of lenvatinib plus pembrolizumab in patients with recurrent mismatch repair-proficient (pMMR) endometrial cancer who had progressed after first-line chemotherapy., Methods: A Markov model was created to simulate the clinical trajectory of 10,000 patients with recurrent pMMR endometrial cancer. The initial decision point in the model was treatment with ether lenvatinib plus pembrolizumab or chemotherapy (doxorubicin or dose-dense paclitaxel). Model probabilities, utility values and costs were derived with assumptions drawn from published literature. A cycle length of 3 months and a time horizon of 2 years was used. The effectiveness was calculated in terms of average quality adjusted life years (QALYs) gained. The primary outcome was incremental cost-effectiveness ratios (ICERs), expressed in 2020 US dollars/QALYs. One-way, two-way and probabilistic sensitivity analyses were performed., Results: Chemotherapy was the least costly strategy at $66,693 followed by lenvatinib plus pembrolizumab ($193,590). Lenvatinib plus pembrolizumab resulted in more patients being alive at 2 years (lenvatinib plus pembrolizumab: 367, chemotherapy: 109). Chemotherapy was cost-effective compared with lenvatinib plus pembrolizumab (ICER: $164,493/QALYs). Lenvatinib plus pembrolizumab became cost-effective when its cost was reduced by $1553 per month (7.8% reduction)., Conclusion: For patients with recurrent pMMR endometrial cancer Lenvatinib plus pembrolizumab is associated with greater survival but is more costly than chemotherapy. The cost of lenvatinib and pembrolizumab would have to be reduced by approximately 7% to be considered cost-effective., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
12. Region of origin and cervical cancer stage in multiethnic Hispanic/Latinx patients living in the United States.
- Author
-
Dinicu AI, Dioun S, Goldberg M, Crookes DM, Wang Y, and Tergas AI
- Subjects
- Female, Humans, Educational Status, Hispanic or Latino, United States epidemiology, Uterine Cervical Neoplasms epidemiology
- Abstract
Background: Hispanic/Latinx people have the second highest cervical cancer incidence rates in the U.S. However, there is a lack of disaggregated data on clinical outcomes for this diverse and populous group, which is critical to direct resources and funding where they are most needed. This study assessed differences in stage at diagnosis of cervical cancer among Hispanic/Latinx subpopulations and associated factors., Methods: We analyzed patients with primary cervical cancer from 2004 to 2019 in the National Cancer Database. Hispanic/Latinx patients were further categorized into Mexican, Puerto Rican (PR), Cuban, Dominican, and Central/South American, as per standard NCDB categories, and evaluated based on stage at diagnosis and sociodemographic characteristics. Multinomial logistic regression quantified the odds of advanced stage at presentation. Regression models were adjusted for age, education, neighborhood income, insurance status, and additional factors., Results: Hispanic/Latinx cervical cancer patients were more likely to be uninsured (18.9% vs. 6.0%, p < 0.001) and more likely to live in low-income neighborhoods (28.6% vs. 16.9%, p < 0.001) when compared to non-Hispanic White populations. Uninsured Hispanic/Latinx patients had 37.0% higher odds of presenting with regional versus localized disease (OR 1.37; 95% CI, 1.19-1.58) and 47.0% higher odds of presenting with distant versus. Localized disease than insured patients (OR 1.47; 95% CI, 1.33-1.62). When adjusting for age, education, neighborhood income, and insurance status, PR patients were 48% more likely than Mexican patients to present with stage IV versus stage I disease (OR 1.48; 95% CI, 1.34-1.64)., Conclusion: Disaggregating health data revealed differences in stage at cervical cancer presentation among Hispanic/Latinx subpopulations, with insurance status as a major predictor. Further work targeting structural factors, such as insurance status, within specific Hispanic/Latinx subpopulations is needed., (© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
13. Authors' reply.
- Author
-
Dioun S and Wright JD
- Published
- 2023
- Full Text
- View/download PDF
14. Association between neighborhood socioeconomic status, built environment and SARS-CoV-2 infection among cancer patients treated at a Tertiary Cancer Center in New York City.
- Author
-
Dioun S, Chen L, Hillyer G, Tatonetti NP, May BL, Melamed A, and Wright JD
- Subjects
- Humans, Ethnicity, Cross-Sectional Studies, SARS-CoV-2, Crowding, New York City epidemiology, RNA, Viral, Minority Groups, Family Characteristics, Social Class, Built Environment, COVID-19, Neoplasms
- Abstract
Background: Racial and ethnic minority groups experience a disproportionate burden of SARS-CoV-2 illness and studies suggest that cancer patients are at a particular risk for severe SARS-CoV-2 infection., Aims: The objective of this study was examine the association between neighborhood characteristics and SARS-CoV-2 infection among patients with cancer., Methods and Results: We performed a cross-sectional study of New York City residents receiving treatment for cancer at a tertiary cancer center. Patients were linked by their address to data from the US Census Bureau's American Community Survey and to real estate tax data from New York's Department of City Planning. Models were used to both to estimate odds ratios (ORs) per unit increase and to predict probabilities (and 95% CI) of SARS-CoV2 infection. We identified 2350 New York City residents with cancer receiving treatment. Overall, 214 (9.1%) were infected with SARS-CoV-2. In adjusted models, the percentage of Hispanic/Latino population (aOR = 1.01; 95% CI, 1.005-1.02), unemployment rate (aOR = 1.10; 95% CI, 1.05-1.16), poverty rates (aOR = 1.02; 95% CI, 1.0002-1.03), rate of >1 person per room (aOR = 1.04; 95% CI, 1.01-1.07), average household size (aOR = 1.79; 95% CI, 1.23-2.59) and population density (aOR = 1.86; 95% CI, 1.27-2.72) were associated with SARS-CoV-2 infection., Conclusion: Among cancer patients in New York City receiving anti-cancer therapy, SARS-CoV-2 infection was associated with neighborhood- and building-level markers of larger household membership, household crowding, and low socioeconomic status., Novelty and Impact: We performed a cross-sectional analysis of residents of New York City receiving treatment for cancer in which we linked subjects to census and real estate date. This linkage is a novel way to examine the neighborhood characteristics that influence SARS-COV-2 infection. We found that among patients receiving anti-cancer therapy, SARS-CoV-2 infection was associated with building and neighborhood-level markers of household crowding, larger household membership, and low socioeconomic status. With ongoing surges of SARS-CoV-2 infections, these data may help in the development of interventions to decrease the morbidity and mortality associated with SARS-CoV-2 among cancer patients., (© 2022 The Authors. Cancer Reports published by Wiley Periodicals LLC.)
- Published
- 2023
- Full Text
- View/download PDF
15. Dostarlimab for recurrent mismatch repair-deficient endometrial cancer: A cost-effectiveness study.
- Author
-
Dioun S, Chen L, Melamed A, Gockley A, St Clair CM, Hou JY, Khoury-Collado F, Hur C, Elkin E, Accordino M, Hershman DL, and Wright JD
- Subjects
- Humans, Female, Cost-Benefit Analysis, Neoplasm Recurrence, Local drug therapy, Quality-Adjusted Life Years, DNA Mismatch Repair, Endometrial Neoplasms drug therapy, Endometrial Neoplasms genetics
- Abstract
Objective: Patients with recurrent endometrial cancer treated with carboplatin and paclitaxel whose disease progresses have few effective treatment options. Based on promising clinical trial data, the anti-programmed cell death 1 (anti-PD-1) antibody dostarlimab was recently granted accelerated approval for endometrial cancer by the US Food and Drug Administration. We developed a decision model to examine the cost-effectiveness of dostarlimab for patients with progressive/recurrent deficient mismatch repair (dMMR) endometrial cancer whose disease has progressed with first-line chemotherapy., Design: Cost-effectiveness study., Population: Hypothetical cohort of 6000 women with progressive/recurrent dMMR endometrial cancer., Methods: The initial decision point in the Markov model was treatment with dostarlimab, pembrolizumab or pegylated liposomal doxorubicin (PLD). Model probabilities, and cost and utility values were derived with assumptions drawn from published literature. Effectiveness was estimated as average quality-adjusted life years (QALYs) gained. One-way, two-way and probabilistic sensitivity analyses were performed to vary the assumptions across a range of plausible values., Main Outcome Measures: The primary outcome was the incremental cost-effectiveness ratio (ICER)., Results: Pegylated liposomal doxorubicin (PLD) was the least costly strategy, at $55,732, followed by dostarlimab ($151,533) and pembrolizumab ($154,597). Based on a willingness-to-pay threshold of $100,000/QALY, PLD was cost-effective compared with dostarlimab, with an ICER of $331,913 per QALY gained for dostarlimab, whereas pembrolizumab was ruled out by extended dominance (less effective, more costly), compared with dostarlimab. In one-way sensitivity analyses, dostarlimab was cost-effective when its cost was reduced to $4905 (52% reduction). These results were robust in a variety of sensitivity analyses., Conclusions: Dostarlimab is associated with greater survival compared with other treatments for women with recurrent dMMR endometrial cancer. Although the agent is substantially more costly, dostarlimab became cost-effective when its cost was reduced to $5489 per cycle., (© 2022 John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
16. Uptake and outcomes of sentinel lymph node mapping in women undergoing minimally invasive surgery for endometrial cancer.
- Author
-
Dioun S, Chen L, Melamed A, Gockley A, St Clair CM, Hou JY, Khoury-Collado F, Hershman DL, and Wright JD
- Subjects
- Female, Humans, Lymph Node Excision, Lymph Nodes pathology, Lymph Nodes surgery, Lymphatic Metastasis pathology, Neoplasm Staging, Retrospective Studies, Sentinel Lymph Node Biopsy, Endometrial Neoplasms pathology, Endometrial Neoplasms surgery, Laparoscopy, Sentinel Lymph Node pathology, Sentinel Lymph Node surgery
- Abstract
Objective: To examine the patterns and outcomes of sentinel lymph node (SLN) assessment in women with endometrial cancer., Design: Retrospective cohort study., Setting: United States inpatient and outpatient hospital services., Population: Women with endometrial cancer who underwent a laparoscopic or robotic-assisted hysterectomy., Methods: The Perspective Database from 2012 to 2018 was used. Performance of lymph node dissection was classified as SLN mapping, lymph node dissection or no nodal evaluation. Adjusted regression models were developed to examine the association between SLN mapping and morbidity and cost., Main Outcome Measures: Utilisation rates, morbidity and cost of both lymph node dissection and SLN mapping., Results: Among 45 381 patients, SLN mapping was performed for 7768 patients (17.1%), lymph node dissection was performed for 23 214 patients (51.2%) and no lymphatic evaluation was performed for 14 399 patients (31.7%). SLN mapping increased from 1.8% in 2012 to 35.3% in 2018, whereas the rate of lymph node dissection decreased from 63.5% to 39.1% (p < 0.001). Among women who underwent nodal evaluation, residence in the west, White race and use of robotic-assisted hysterectomy were associated with SLN mapping (p < 0.05 for all). The complication rate was 5.9% for SLN mapping, compared with 7.3% in those that underwent lymph node dissection (aRR 0.85, 95% CI 0.77-0.95). The median hospital costs for women who underwent SLN mapping ($10 479) and lymph node dissection ($10 747) were higher than for those who did not undergo nodal assessment ($9149) (p < 0.001)., Conclusions: The performance of SLN mapping is increasing for endometrial cancer. Compared with lymph node dissection, SLN mapping is associated with lower morbidity. SLN mapping significantly increases the costs compared with hysterectomy alone., Tweetable Abstract: SLN mapping is increasing rapidly for endometrial cancer and is associated with decreased perioperative morbidity., (© 2021 John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
17. Role of tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: Systematic review and meta-analysis.
- Author
-
Guida F, Dioun S, Fagotti A, Melamed A, Grossi A, Scambia G, Wright JD, and Tergas AI
- Subjects
- Carcinoma, Ovarian Epithelial surgery, Female, Humans, Prognosis, Cytoreduction Surgical Procedures methods, Ovarian Neoplasms drug therapy
- Abstract
Objective: To evaluate the clinical utility of tertiary cytoreductive surgery (TCS) in recurrent ovarian cancer., Methods: MEDLINE via PubMed, Embase (Elsevier), ClinicalTrials.gov, Scopus (Elsevier) and Web of Science for studies from inception to 4/09/2021. Studies reporting disease specific survival (DSS) and overall survival (OS) among women who underwent optimal cytoreductive surgery as compared to those who had a suboptimal cytoreductive surgery at time of TCS were abstracted. Study quality was assessed with the Quality In Prognosis Studies (QUIPS) tool. The data were extracted independently by multiple observers. Random-effects models were used to pool associations and to analyze the association between survival and surgical outcomes., Results: 10 studies met all the criteria for inclusion in the systematic review. Patients with optimal tertiary cytoreductive surgery had better DSS (HR = 0.35; 95% CI, 0.19-0.64, P < 0.001), with low heterogeneity (I
2 = 0%, P = 0.41) when compared to those with suboptimal tertiary cytoreductive surgery. Pooled results from these studies also demonstrated a better OS (HR = 0.34; 95% CI, 0.15-0.74, P < 0.007) with moderate heterogeneity (I2 = 59%, P = 0.09) when compared to patients with a suboptimal tertiary cytoreductive surgery. This remained significant in a series of sensitivity analyses. Due to the limited number of studies, we were unable to do further subgroup analyses looking at outcomes comparing tertiary cytoreductive surgery to chemotherapy., Conclusion: In this systematic review and meta-analysis of observational studies examining tertiary cytoreductive surgery for recurrent ovarian cancer, optimal tertiary cytoreductive surgery was associated with improved OS and DSS survival compared to suboptimal tertiary cytoreductive surgery., (Copyright © 2022 Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
18. Trends in the Use of Minimally Invasive Adnexal Surgery in the United States.
- Author
-
Dioun S, Huang Y, Melamed A, Gockley A, St Clair CM, Hou JY, Tergas AI, Khoury-Collado F, Hershman DL, and Wright JD
- Subjects
- Adnexal Diseases mortality, Adnexal Diseases surgery, Adolescent, Adult, Aged, Cohort Studies, Female, Genital Diseases, Female mortality, Gynecologic Surgical Procedures statistics & numerical data, Gynecologic Surgical Procedures trends, Humans, Laparoscopy statistics & numerical data, Laparotomy statistics & numerical data, Middle Aged, Minimally Invasive Surgical Procedures statistics & numerical data, Ovariectomy statistics & numerical data, United States epidemiology, Young Adult, Cysts surgery, Genital Diseases, Female surgery, Minimally Invasive Surgical Procedures trends, Ovariectomy trends, Ovary surgery
- Abstract
Objective: To examine the utilization of minimally invasive adnexal surgery, including ovarian cystectomy and oophorectomy, among women with benign gynecologic diseases and compare the associated morbidity and mortality of minimally invasive and open surgery., Methods: Women with benign ovarian pathology who underwent an ovarian cystectomy or oophorectomy from 2016 through 2018 in the Nationwide Ambulatory Surgery Sample and Nationwide Inpatient Sample databases were included. Patients with a diagnosis of gynecologic malignancy or concurrent hysterectomy were excluded. Population-level weighted estimates were developed, and perioperative morbidity, mortality, and hospital charges were examined based on surgical approach for each procedure., Results: The cohort included 351,207 women who underwent oophorectomy and 220,893 women who underwent cystectomy, when weighted representing 547,836 and 328,408 patients, respectively, nationwide. A minimally invasive surgical approach was used in 294,190 (89.6%) patients who underwent ovarian cystectomy, and in 478,402 (87.3%) of patients who underwent oophorectomy. Use of minimally invasive surgery for cystectomy increased from 88.7% in 2016 to 91.0% in 2018, and the rate of minimally invasive surgery for oophorectomy increased from 85.8% to 88.7% over the same time period (P<.001 for both). The complication rates for ovarian cystectomy were 2.7% for minimally invasive surgery and 8.8% for laparotomy (P<.001); for oophorectomy the complication rate was 3.1% for minimally invasive surgery and 22.9% for laparotomy (P<.001)., Conclusion: Minimally invasive surgery is used in the majority of women who are undergoing oophorectomy and ovarian cystectomy for benign indications. Compared with laparotomy, minimally invasive surgery is associated with fewer complications., Competing Interests: Financial Disclosure Dr. Wright has served as a consultant for Clovis Oncology, has received research support from Merck, and has received royalties from UpToDate. Dr. Hou has served as a consultant for Foundation Medicine. Dr. Tergas receives payments from Immunomics and Auro Vaccines. The other authors did not report any potential conflicts of interest., (Copyright © 2021 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
19. Intraoperative Rupture of the Ovarian Capsule in Early-Stage Ovarian Cancer: A Meta-analysis.
- Author
-
Dioun S, Wu J, Chen L, Kaplan S, Huang Y, Melamed A, Gockley A, St Clair CM, Hou JY, Tergas AI, Khoury-Collado F, Machida H, Mikami M, Matsuo K, Hershman DL, and Wright JD
- Subjects
- Disease Progression, Female, Humans, Ovarian Neoplasms mortality, Survival Rate, Intraoperative Complications, Ovarian Neoplasms surgery, Ovary injuries, Progression-Free Survival, Rupture
- Abstract
Objective: To examine the effects of intraoperative ovarian capsule rupture on progression-free survival and overall survival in women who are undergoing surgery for early-stage ovarian cancer., Data Sources: MEDLINE using PubMed, EMBASE (Elsevier), ClinicalTrials.gov, and Scopus (Elsevier) were searched from inception until August 11, 2020., Methods of Study Selection: High-quality studies reporting survival outcomes comparing ovarian capsule rupture to no capsule rupture among patients with early-stage epithelial ovarian cancer who underwent surgical management were abstracted. Study quality was assessed with the Newcastle-Ottawa Scale, and studies with scores of at least 7 points were included., Tabulation, Integration, and Results: The data were extracted independently by multiple observers. Random-effects models were used to pool associations and to analyze the association between ovarian capsule rupture and oncologic outcomes. Seventeen studies met all the criteria for inclusion in the meta-analysis. Twelve thousand seven hundred fifty-six (62.6%) patients did not have capsule rupture and had disease confined to the ovary on final pathology; 5,532 (33.7%) patients had intraoperative capsule rupture of an otherwise early-stage ovarian cancer. Patients with intraoperative capsule rupture had worse progression-free survival (hazard ratio [HR] 1.92, 95% CI 1.34-2.76, P<.001), with moderate heterogeneity (I2=41%, P=.07) when compared with those without capsule rupture. Pooled results from these studies showed a worse overall survival (HR 1.48, 95% CI 1.15-1.91, P=.003), with moderate heterogeneity (I2=53%, P=.02) when compared with patients without intraoperative capsule rupture. This remained significant in a series of sensitivity analyses., Conclusion: This systematic review and meta-analysis of high-quality observational studies shows that intraoperative ovarian capsule rupture results in decreased progression-free survival and overall survival in women with early-stage ovarian cancer who are undergoing initial surgical management., Systematic Review Registration: PROSPERO, CRD42021216561., Competing Interests: Financial Disclosure Dr. Hou has served as a consultant for Foundation Medicine. Dr. Tergas reports money was paid to her from Auro Vaccines. Dr. Matsuo received an honorarium from Chugai and investigator meeting attendance expense from VBL Therapeutics outside this study. Dr. Wright has served as a consultant for Clovis Oncology, received royalties from UpToDate, and received research support from Merck. The other authors did not report any potential conflicts of interest., (Copyright © 2021 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
20. Uptake and Outcomes of Sentinel Lymph Node Mapping in Women With Atypical Endometrial Hyperplasia.
- Author
-
Dioun S, Chen L, Melamed A, Gockley A, St Clair CM, Hou JY, Tergas AI, Khoury-Collado F, Hur C, Hershman DL, and Wright JD
- Subjects
- Adult, Aged, Aged, 80 and over, Cost-Benefit Analysis, Female, Humans, Hysterectomy, Middle Aged, New York, Robotic Surgical Procedures, Endometrial Hyperplasia pathology, Sentinel Lymph Node pathology, Sentinel Lymph Node Biopsy economics
- Abstract
Objective: To examine the utilization, morbidity, and cost of sentinel lymph node mapping in women undergoing hysterectomy for complex atypical endometrial hyperplasia., Methods: Women with complex atypical endometrial hyperplasia who underwent hysterectomy from 2012 to 2018 in the Perspective database were examined. Perioperative morbidity, mortality, and cost were examined based on performance of sentinel lymph node mapping, lymph node dissection or no nodal evaluation., Results: Among 10,266 women, sentinel lymph node mapping was performed in 620 (6.0%), lymph node dissection in 538 (5.2%), and no lymphatic evaluation in 9,108 (88.7%). Use of sentinel lymph node mapping increased from 0.8% in 2012 to 14.0% in 2018, and the rate of lymph node dissection rose from 5.7% to 6.4% (P<.001). In an adjusted model, residence in the western United States, treatment by high-volume hospitals and use of robotic-assisted hysterectomy were associated with sentinel lymph node mapping (P<.05 for all). The complication rates were similar between the three groups. The median cost for sentinel lymph node mapping ($9,673) and lymph node dissection ($9,754) were higher than in those who did not undergo nodal assessment ($8,435) (P<.001)., Conclusion: Performance of sentinel lymph node mapping is increasing rapidly for women with complex atypical endometrial hyperplasia but is not associated with increased perioperative morbidity or mortality., Competing Interests: Financial Disclosure Dr. Wright has served as a consultant for Clovis Oncology and received research support from Merck. Dr. Hou has served as a consultant for Foundation Medicine. Dr. Hur has served as a consultant for Kite Pharmaceuticals and has equity in Cambridge Biomedical Economic Consulting Group. The other authors did not disclose any potential conflicts of interest., (Copyright © 2021 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
21. Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: A prospective study.
- Author
-
Stewart KI, Chasen B, Erwin W, Fleming N, Westin SN, Dioun S, Frumovitz M, Ramirez PT, Lu KH, Wong F, Aloia TA, and Soliman PT
- Subjects
- Adult, Aged, Aged, 80 and over, Endometrial Neoplasms surgery, Endometrium pathology, Endometrium surgery, False Negative Reactions, Feasibility Studies, Female, Fluorodeoxyglucose F18 administration & dosage, Humans, Hysterectomy, Middle Aged, Peritoneal Neoplasms secondary, Predictive Value of Tests, Prospective Studies, Radiopharmaceuticals, Reproducibility of Results, Salpingo-oophorectomy, Sentinel Lymph Node diagnostic imaging, Sentinel Lymph Node pathology, Sentinel Lymph Node Biopsy, Endometrial Neoplasms pathology, Lymphatic Metastasis diagnostic imaging, Peritoneal Neoplasms diagnostic imaging, Positron Emission Tomography Computed Tomography statistics & numerical data, Preoperative Care statistics & numerical data
- Abstract
Background: The identification of extrauterine disease is critical to the management of patients with high-risk endometrial cancer. The purpose of the current study was to determine the accuracy of preoperative positron emission tomography (PET)/computed tomography (CT) in the detection of extrauterine disease., Methods: Women with high-risk endometrial cancer were enrolled prospectively and underwent preoperative PET/CT followed by surgery, including sentinel lymph node biopsy and lymphadenectomy. Primary tumor factors on PET/CT were correlated with lymph node pathology. The sensitivity, specificity, positive predictive value, and negative predictive value were calculated for the detection of lymphadenopathy and peritoneal disease by PET/CT., Results: A total of 112 patients were enrolled and underwent PET/CT between April 2013 and May 2016, 108 of whom were evaluable. On PET/CT, 21 patients (19.4%) were found to have extrauterine disease, 18 (17%) had positive lymph nodes, and 8 (7%) had peritoneal disease. A total of 108 patients underwent surgery, 103 of whom (95%) underwent lymphadenectomy. The sensitivity of PET/CT to detect positive lymph nodes was 45.8%, with a specificity of 91.1%, positive predictive value of 61.1%, and negative predictive value of 84.7%. The false-negative rate was 54.2%. There was no difference in primary tumor characteristics on imaging noted between patients with positive and negative lymph nodes. The sensitivity of PET/CT to detect peritoneal disease was 37.5%, with a specificity of 97.8%, positive predictive value of 75%, and negative predictive value of 90.0%. The false-negative rate was 62.5%., Conclusions: Preoperative PET/CT did not reliably predict the presence of extrauterine disease in women with high-risk endometrial cancer. Given the high false-negative rates, PET/CT should not be used in the preoperative treatment planning of these patients., (© 2019 American Cancer Society.)
- Published
- 2019
- Full Text
- View/download PDF
22. Unplanned hospitalizations in a racially and ethnically diverse population of women receiving chemotherapy for epithelial ovarian cancer.
- Author
-
Dioun S, Jorgensen JR, Miller EM, Tymon-Rosario J, Xie X, Xue X, Kuo DY, and Nevadunsky NS
- Subjects
- Aged, Aged, 80 and over, Body Mass Index, Carcinoma, Ovarian Epithelial, Chemotherapy, Adjuvant adverse effects, Chemotherapy, Adjuvant methods, Clinical Decision-Making methods, Comorbidity, Cytoreduction Surgical Procedures, Disease-Free Survival, Female, Humans, Hypertension epidemiology, Middle Aged, Neoadjuvant Therapy adverse effects, Neoadjuvant Therapy methods, Neoplasms, Glandular and Epithelial ethnology, Neoplasms, Glandular and Epithelial mortality, Ovarian Neoplasms ethnology, Ovarian Neoplasms mortality, Retrospective Studies, Risk Assessment methods, Risk Factors, Socioeconomic Factors, Survival Analysis, United States epidemiology, Urban Population statistics & numerical data, Antineoplastic Combined Chemotherapy Protocols adverse effects, Neoplasms, Glandular and Epithelial therapy, Ovarian Neoplasms therapy, Patient Admission statistics & numerical data, Patient Readmission statistics & numerical data, Quality of Health Care
- Abstract
Objectives: Unplanned hospital admission following chemotherapy is a measure of quality cancer care. Large retrospective datasets have shown admission rates of 10-35% for women with ovarian cancer receiving chemotherapy. We sought to evaluate the prevalence and associated risk factors for hospital admission following chemotherapy in our racially diverse urban population., Methods: After IRB approval, clinicopathologic and treatment data were abstracted from all patients with newly diagnosed epithelial ovarian cancer who received chemotherapy at our institution from 2005 to 2016. Two-sided statistical analyses and Cox regression analysis were performed using Stata., Results: Of 217 evaluable patients, 87 (40%) had unplanned admissions following chemotherapy: adjuvant 64 (74%) and neoadjuvant 23(26%). Thirty (14%) had more than one admission. In total, there were 1314 days of hospitalization. The median readmission duration was 3 days. Body mass index and hypertension were predictive of readmission (p < 0.05). When comparing those readmitted more than once to those admitted once, both race and aspirin use were predictive of readmission (p < 0.05). Of those admitted more than once the self-identified race and ethnicity was 12 (40%) Hispanic, 8 (27%) White, 8 (27%) Black and 2 (7%) other. There was a significant difference in disease free (p = 0.01) and overall survival (p = 0.004) for patients with unplanned admission after chemotherapy as compared to those without admission., Conclusions: Readmission rates in our racially diverse patient population were higher than previously reported in the literature. Identifying patients at risk of readmission may play a role in chemotherapy decision-making, and resource allocation including patient care navigators., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
23. A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer.
- Author
-
Soliman PT, Westin SN, Dioun S, Sun CC, Euscher E, Munsell MF, Fleming ND, Levenback C, Frumovitz M, Ramirez PT, and Lu KH
- Subjects
- Adenocarcinoma, Clear Cell diagnostic imaging, Adenocarcinoma, Clear Cell surgery, Adult, Aged, Aged, 80 and over, Carcinoma, Endometrioid diagnostic imaging, Carcinoma, Endometrioid surgery, Carcinosarcoma diagnostic imaging, Carcinosarcoma surgery, Coloring Agents, Endometrial Neoplasms diagnostic imaging, Female, Humans, Indocyanine Green, Middle Aged, Neoplasm Staging, Neoplasms, Cystic, Mucinous, and Serous diagnostic imaging, Neoplasms, Cystic, Mucinous, and Serous surgery, Positron Emission Tomography Computed Tomography, Prospective Studies, Adenocarcinoma, Clear Cell pathology, Carcinoma, Endometrioid pathology, Carcinosarcoma pathology, Endometrial Neoplasms pathology, Neoplasms, Cystic, Mucinous, and Serous pathology, Sentinel Lymph Node pathology, Sentinel Lymph Node Biopsy methods
- Abstract
Objective: Sentinel lymph node (SLN) mapping continues to evolve in the surgical staging of endometrial cancer (EC). The purpose of this trial was to identify the sensitivity, false negative rate (FNR) and FN predictive value (FNPV) of SLN compared to complete pelvic and para-aortic lymphadenectomy (LAD) in women with high-risk EC., Methods: Women with high-risk EC (grade 3, serous, clear cell, carcinosarcoma) were enrolled in this prospective surgical trial. All patients underwent preoperative PET/CT and intraoperative SLN biopsy followed by LAD. Patients with peritoneal disease on imaging or at the time of surgery were excluded. Patients were evaluable if SLN was attempted and complete LAD was performed., Results: 123 patients were enrolled between 4/13 and 5/16; 101 were evaluable. At least 1 SLN was identified in 89% (90); bilateral detection 58%, unilateral pelvic 40%, para-aortic only 2%. Indocyanine green was used in 61%, blue dye in 28%, and blue dye and technetium in 11%. Twenty-three pts. (23%) had ≥1 positive node. In 20/23, ≥1 SLN was identified and in 19/20 the SLN was positive. Only 1 patient had bilateral negative SLN and positive non-SLNs on final pathology. Overall, sensitivity of SLN was 95% (19/20), FNR was 5% (1/20) and FNPV was 1.4% (1/71). If side-specific LAD was performed when a SLN was not detected, the FNR decreased to 4.3% (1/23)., Conclusion: This prospective trial demonstrated that SLN biopsy plus side-specific LAD, when SLN is not detected, is a reasonable alternative to a complete LAD in high-risk endometrial cancer., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.